Income Statement APT Medical Inc.
Equities
688617
CNE100004C45
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 230.91 CNY | +1.54% |
|
-6.23% | -5.08% |
| 02-27 | APT Medical's Attributable Profit Jumps 22% in 2025; Shares Surge 7% | MT |
| 02-26 | APT Medical Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
Revenues | 478M | 823M | 1.2B | 1.64B | 2.05B | |||
Other Revenues, Total | 1.5M | 5.82M | 11.55M | 8.49M | 16.62M | |||
Total Revenues | 479M | 829M | 1.22B | 1.65B | 2.07B | |||
Cost of Goods Sold, Total | 142M | 259M | 354M | 486M | 580M | |||
Gross Profit | 337M | 570M | 862M | 1.16B | 1.49B | |||
Selling General & Admin Expenses, Total | 153M | 250M | 308M | 387M | 464M | |||
Provision for Bad Debts | 283K | -511K | 790K | -178K | 2.22M | |||
R&D Expenses | 71.9M | 135M | 175M | 238M | 291M | |||
Other Operating Expenses | 6.14M | 8.14M | 13.75M | 14.52M | 15.22M | |||
Other Operating Expenses, Total | 232M | 393M | 497M | 639M | 772M | |||
Operating Income | 106M | 177M | 365M | 525M | 714M | |||
Interest Expense, Total | -1.41M | -1.63M | -1.45M | -3.69M | -2.01M | |||
Interest And Investment Income | 1.21M | 13.26M | 23.94M | 27.74M | 25.23M | |||
Net Interest Expenses | -207K | 11.64M | 22.49M | 24.05M | 23.23M | |||
Currency Exchange Gains (Loss) | -431K | -1M | 1.17M | 2.66M | 2.83M | |||
Other Non Operating Income (Expenses) | -334K | -499K | -490K | -35.61K | -817K | |||
EBT, Excl. Unusual Items | 105M | 187M | 388M | 552M | 739M | |||
Impairment of Goodwill | - | - | - | -3.84M | - | |||
Gain (Loss) On Sale Of Investments | -67.73K | 21.72M | 342K | - | -16.7M | |||
Gain (Loss) On Sale Of Assets | -231K | -51.8K | 56.21K | 11.97M | 253K | |||
Asset Writedown | - | -3.5M | -10.68M | -123K | -833K | |||
Other Unusual Items | 16.83M | 16.58M | 17.25M | 36.83M | 24.42M | |||
EBT, Incl. Unusual Items | 121M | 222M | 395M | 596M | 746M | |||
Income Tax Expense | 17.02M | 26.7M | 54.98M | 74.24M | 87.8M | |||
Earnings From Continuing Operations | 104M | 195M | 340M | 522M | 658M | |||
Net Income to Company | 104M | 195M | 340M | 522M | 658M | |||
Minority Interest | 6.58M | 13.07M | 17.86M | 11.79M | 14.98M | |||
Net Income - (IS) | 111M | 208M | 358M | 534M | 673M | |||
Net Income to Common Incl Extra Items | 111M | 208M | 358M | 534M | 673M | |||
Net Income to Common Excl. Extra Items | 111M | 208M | 358M | 534M | 673M | |||
Per Share Items | ||||||||
Net EPS - Basic | 1.06 | 1.52 | 2.56 | 3.82 | 4.8 | |||
Basic EPS - Continuing Operations | 1.06 | 1.52 | 2.56 | 3.82 | 4.8 | |||
Basic Weighted Average Shares Outstanding | 105M | 137M | 140M | 140M | 140M | |||
Net EPS - Diluted | 1.06 | 1.51 | 2.52 | 3.77 | 4.77 | |||
Diluted EPS - Continuing Operations | 1.06 | 1.51 | 2.52 | 3.77 | 4.77 | |||
Diluted Weighted Average Shares Outstanding | 105M | 138M | 142M | 142M | 141M | |||
Normalized Basic EPS | 0.69 | 0.95 | 1.86 | 2.55 | 3.4 | |||
Normalized Diluted EPS | 0.69 | 0.94 | 1.83 | 2.52 | 3.38 | |||
Dividend Per Share | 0.24 | 0.48 | 0.78 | 0.95 | 1.21 | |||
Payout Ratio | 1.28 | 15.97 | 19.28 | 21.02 | 19.9 | |||
Supplemental Items | ||||||||
EBITDA | 125M | 204M | 405M | 580M | 790M | |||
EBITA | 108M | 177M | 367M | 528M | 719M | |||
EBIT | 106M | 177M | 365M | 525M | 714M | |||
EBITDAR | 128M | 205M | 406M | 581M | 796M | |||
Total Revenues (As Reported) | 479M | 829M | 1.22B | 1.65B | 2.07B | |||
Effective Tax Rate - (Ratio) | 14.04 | 12.05 | 13.91 | 12.45 | 11.77 | |||
Total Current Taxes | 17.33M | 34.9M | 55.62M | 79.14M | 103M | |||
Total Deferred Taxes | -307K | -8.2M | -642K | -4.9M | -15.13M | |||
Normalized Net Income | 72.01M | 130M | 260M | 357M | 477M | |||
Interest Capitalized | 131K | 82.6K | - | - | - | |||
Interest on Long-Term Debt | - | 522K | 436K | 693K | 539K | |||
Supplemental Operating Expense Items | ||||||||
Marketing Expenses | 21.01M | 33M | 41.59M | 46.16M | 57.73M | |||
Selling and Marketing Expenses | 114M | 195M | 241M | 305M | 373M | |||
General and Administrative Expenses | 39.56M | 55.12M | 66.55M | 82.26M | 91.52M | |||
Research And Development Expense From Footnotes | 71.9M | 135M | 175M | 238M | 291M | |||
Net Rental Expense, Total | 2.3M | 741K | 726K | 933K | 5.63M | |||
Imputed Operating Lease Interest Expense | 321K | 237K | 170K | 387K | 1.79M | |||
Imputed Operating Lease Depreciation | 1.98M | 505K | 556K | 547K | 3.84M | |||
Stock-Based Comp., R&D Exp. (Total) | - | 9.17M | 11.43M | 8.96M | 3.34M | |||
Stock-Based Comp., S&M Exp. (Total) | - | 4.06M | 4.09M | 3.46M | 1.57M | |||
Stock-Based Comp., G&A Exp. (Total) | - | 3.96M | 4.63M | 5.07M | 1.92M | |||
Stock-Based Comp., Other (Total) | - | 971K | 1.6M | 829K | 408K | |||
Total Stock-Based Compensation | - | 18.17M | 21.75M | 18.32M | 7.24M |
- Stock Market
- Equities
- 688617 Stock
- Financials APT Medical Inc.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















